MedTrace Logo

A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions

NCT00633516 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2022-11-01

No results posted yet for this study

Summary

The incidence of malignant melanoma has increased dramatically in recent decades. In 1930, the lifetime risk of an individual in the United States developing melanoma was 1 in 1,500. This has been exponentially increasing over the years with the risk estimated to be 1 in 75 in 2000 . According to the American Cancer Society, approximately 59,580 new cases of melanoma will be diagnosed in the United States in 2005 and about 7,770 people are expected to die of the disease.

Conditions

Interventions

DEVICE

Optical Spectroscopy

Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy

Sponsors & Collaborators

  • Beckman Laser Institute University of California Irvine

    collaborator OTHER

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • David JB Hsiang, MD · Beckman Laser Institute University of California Irvine

  • Bruce Tromberg, PhD · Beckman Laser Institute University of California Irvine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00633516 on ClinicalTrials.gov